Manufacturer
Sun Pharmaceutical Industries Limited
Contents
Esomeprazole.
Indication
Treatment of Gastroesophageal Reflux Disease (GERD)/ Risk Reduction of NSAID-Associated Gastric Ulcer/ H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence
Instruction
Delayed-Release Cap: Should be taken on an empty stomach. Take 1 hr before meals.
Tab: May be taken with or without food.
Drug interaction
Increased risk of digoxin-induced cardiotoxic effects. May diminish the therapeutic effects of clopidogrel. Increased risk of hypomagnesaemia with diuretics. May increase serum concentrations of tacrolimus, methotrexate, cilostazol, and drugs metabolised by CYP2C19 (e.g. diazepam, citalopram, imipramine, phenytoin). May reduce absorption of ketoconazole, itraconazole, Fe salts, erlotinib. Concomitant use with warfarin may increase INR and prothrombin time. Esomeprazole serum levels may be decreased with CYP2C19 or CYP3A4 inducers (e.g. rifampicin) and increased with CYP3A4 inhibitors (e.g. voriconazole, clarithromycin). May prolong elimination half-life of cisapride.
Potentially Fatal: May substantially decrease the serum levels of atazanavir, nelfinavir, or rilpivirine which may lead to the development of drug resistance.
Malaysia
